Alongside this rapid progress, an equally ambitious effort has emerged to construct ethical frameworks for intelligent ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recent discussion of artificial intelligence in intelligence analysis has consistently framed the technology as a means of accelerating an existing process. The intelligence cycle (collection, ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://doi.org/10.2307/j.ctvjnrt76.5 https ...

Recursion Pharmaceuticals (RXRX) has shown volatility recently, with a 3.13% decline on July 8, 2026, amidst broader market movements. The company is preparing for an earnings report, expected to show ...